PolyPeptide Group AG announced that shareholders approved all proposals put forward by the Board of Directors at the company's fifth annual General Meeting with a large majority. The meeting took place at the Chollerhalle in Zug, Switzerland, with 26,780,855 shares with voting rights represented, corresponding to 80.85% of the issued registered shares of the company.
All six members of the Board of Directors proposed for re-election were appointed for a term of office ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term of office ending at the conclusion of the next annual General Meeting 2027.
Further proposals of the Board of Directors that were approved at the AGM 2026 included the re-election of the Statutory Auditors and the Independent Proxy as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. The shareholders also granted discharge to all members of the Board of Directors and Executive Committee in office in the financial year 2025 for their activities in that period.
The shareholders approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements and the report on non-financial matters, in each case, for the financial year 2025 as well as the Remuneration Report 2025 in a separate consultative vote. The minutes of the AGM 2026 will be available within 15 days on the company's website at https://polypeptide.com.
The next annual General Meeting 2027 will be held on 7 April 2027. PolyPeptide Group AG is a specialized Contract Development & Manufacturing Organization for peptide-based active pharmaceutical ingredients, serving customers mainly in pharma and biotech. The company contributes to the health of millions of patients across the world and offers products and services from pre-clinical to commercial stages, with significant exposure to metabolic diseases including GLP-1 therapies.
This shareholder approval demonstrates strong confidence in the company's leadership and strategic direction during a period of significant growth in the peptide therapeutics market. The unanimous support for all board proposals suggests alignment between management and investors regarding corporate governance and financial management. For stakeholders in the pharmaceutical manufacturing sector, this outcome indicates stability in PolyPeptide's operations as it continues to expand its global network of six GMP-certified facilities in Europe, the U.S. and India.
